| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Pulmonary Biology, Cincinnati Children’s Hospital Medical Center, and University of Cincinnati College of Medicine, and
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45229; and
Departamento de Bioquimica y Biologia Molecular I, Facultad Biologia, Universidad Complutense, Madrid, Spain
Surfactant protein B (SP-B) is secreted into the airspaces with surfactant phospholipids where it reduces surface tension and prevents alveolar collapse at end expiration. SP-B is a member of the saposin-like family of proteins, several of which have antimicrobial properties. SP-B lyses negatively charged liposomes and was previously reported to inhibit the growth of Escherichia coli in vitro; however, a separate study indicated that elevated levels of SP-B in the airspaces of transgenic mice did not confer resistance to infection. The goal of this study was to assess the antimicrobial properties of native SP-B and synthetic peptides derived from the native peptide. Native SP-B aggregated and killed clinical isolates of Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and group B streptococcus by increasing membrane permeability; however, SP-B also lysed RBC, indicating that the membranolytic activity was not selective for bacteria. Both the antimicrobial and hemolytic activities of native SP-B were inhibited by surfactant phospholipids, suggesting that endogenous SP-B may not play a significant role in alveolar host defense. Synthetic peptides derived from native SP-B were effective at killing both Gram-positive and Gram-negative bacteria at low peptide concentrations (0.15–5.0 µM). The SP-B derivatives selectively lysed bacterial membranes and were more resistant to inhibition by phospholipids; furthermore, helix 1 (residues 7–22) retained significant antimicrobial activity in the presence of native surfactant. These results suggest that the role of endogenous SP-B in host defense may be limited; however, synthetic peptides derived from SP-B may be useful in the treatment of bacterial pneumonias.
This article has been cited by other articles:
|
|
 |
|
  M. Halwani, B. Yebio, Z. E. Suntres, M. Alipour, A. O. Azghani, and A. Omri Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa J. Antimicrob. Chemother., December 1, 2008; 62(6): 1291 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kobayashi, T. Yoshida, D. Takeuchi, V. C. Jones, K. Shigematsu, D. N. Herndon, and F. Suzuki Gr-1+CD11b+ cells as an accelerator of sepsis stemming from Pseudomonas aeruginosa wound infection in thermally injured mice J. Leukoc. Biol., June 1, 2008; 83(6): 1354 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Galvan, M. A. S. Lasaro, and D. M. Schifferli Capsular Antigen Fraction 1 and Pla Modulate the Susceptibility of Yersinia pestis to Pulmonary Antimicrobial Peptides Such as Cathelicidin Infect. Immun., April 1, 2008; 76(4): 1456 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Harder, R. Glaser, and J.-M. Schroder Review: Human antimicrobial proteins effectors of innate immunity Innate Immunity, December 1, 2007; 13(6): 317 - 338. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Orgeig, W. Bernhard, S. C. Biswas, C. B. Daniels, S. B. Hall, S. K. Hetz, C. J. Lang, J. N. Maina, A. K. Panda, J. Perez-Gil, et al. The anatomy, physics, and physiology of gas exchange surfaces: is there a universal function for pulmonary surfactant in animal respiratory structures? Integr. Comp. Biol., October 1, 2007; 47(4): 610 - 627. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
